CSIMarket
 
Acadia Pharmaceuticals Inc   (ACAD)
Other Ticker:  
 
 
Price: $18.4800 $-0.25 -1.335%
Day's High: $18.8329 Week Perf: -23.41 %
Day's Low: $ 18.21 30 Day Perf: -27.7 %
Volume (M): 3,760 52 Wk High: $ 33.99
Volume (M$): $ 69,485 52 Wk Avg: $24.51
Open: $18.62 52 Wk Low: $17.71



 Market Capitalization (Millions $) 3,011
 Shares Outstanding (Millions) 163
 Employees 780
 Revenues (TTM) (Millions $) 632
 Net Income (TTM) (Millions $) -149
 Cash Flow (TTM) (Millions $) -57
 Capital Exp. (TTM) (Millions $) 40

Acadia Pharmaceuticals Inc
Acadia Pharmaceuticals Inc is a publicly traded biopharmaceutical company, founded in 1997 in San Diego, California, USA. The company's primary focus is on developing and commercializing drugs that address unmet medical needs in central nervous system (CNS) disorders, such as Parkinson's disease, Alzheimer's disease, schizophrenia, and depression.

Acadia's flagship drug is pimavanserin, which is marketed as Nuplazid. It is the first and only FDA-approved treatment for Parkinson's disease psychosis, a condition that affects up to 50% of Parkinson's disease patients. Pimavanserin selectively targets serotonin 5-HT2A receptors, which are believed to contribute to the hallucinations and delusions experienced by these patients. Nuplazid was approved by the FDA in 2016, and it has since been prescribed to over 200,000 patients.

Acadia also has a pipeline of other CNS drugs in various stages of development. Its product candidates include:

- Trofinetide: A potential treatment for Rett syndrome, a rare genetic disorder that affects mainly girls and causes developmental and cognitive disabilities.
- ACP-044: A potential treatment for schizophrenia and other psychiatric disorders.
- ACP-319: A potential treatment for major depressive disorder and other mood disorders.
- ACP-105: A potential treatment for Alzheimer's disease and other neurodegenerative disorders.

Acadia has partnerships with several pharmaceutical companies, including Eisai, AstraZeneca, and Neuren Pharmaceuticals, to further develop and commercialize some of its products.

Acadia has experienced significant growth in recent years, with a market capitalization of over $5 billion and a workforce of over 1,300 employees. It has received numerous awards and recognitions for its research and development efforts, including being named one of the World's Most Innovative Companies by Forbes in 2014 and receiving the Prix Galien USA award for Best Biotechnology Product in 201

In addition to its focus on developing innovative CNS drugs, Acadia also prioritizes corporate social responsibility and sustainability. It has implemented various programs to reduce its environmental impact, support local communities, and promote diversity and inclusion within its workforce.


   Company Address: 12830 El Camino Real San Diego 92130 CA
   Company Phone Number: 558-2871   Stock Exchange / Ticker: NASDAQ ACAD
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Acadia Pharmaceuticals Inc

Acadia Pharmaceuticals Inc Delivers Impressive Revenue Growth and Promising Outlook, Surpassing Expectations in Latest Financial Report

Acadia Pharmaceuticals Inc, a renowned pharmaceutical company, recently released its financial report for the most recent fiscal period, showcasing both strong revenue growth and significant deficits. Despite the increased deficit per share, the company experienced a substantial rise in revenue and a promising increase in accounts receivable, indicating a potential surge in demand.
Comparing the most recent fiscal period to the same period a year ago, Acadia Pharmaceuticals Inc witnessed a deficit per share of $-0.40, compared to $-0.17 previously. Moreover, their earnings per share fell from $0.01 to $-0.40, demonstrating temporary setbacks in profitability. However, these declines were overshadowed by the impressive revenue growth of 61.956%, rising from $130.71 million to $211.70 million in the same time frame, showcasing the company's ability to generate substantial income.

Acadia Pharmaceuticals Inc

Acadia Pharmaceuticals Inc Smashes Expectations: Soars into Profitability with 22.795% Revenue Boost in Q2 2023, Outperforms Industry Peers!

Acadia Pharmaceuticals Inc: A Strong Quarter Leads to Profitability
Acadia Pharmaceuticals Inc, a major player in the pharmaceutical industry, has witnessed a significant improvement in its financial performance in the second quarter of 2023. This notable revenue improvement has driven the company towards profitability, with a surge in revenue and earnings per share compared to the previous year. Acadia Pharmaceuticals Inc has also seen positive trends in its profit margins, accounts receivables, and stock performance. Let's delve deeper into these financial indicators and analyze the company's current position.
In the second quarter of 2023, Acadia Pharmaceuticals Inc experienced a substantial increase in revenue, with a growth rate of 22.794%. The company's revenue reached $165.24 million, showing significant progress compared to the same period in the previous year. This growth in revenue aligns with the performance of its peers in the Major Pharmaceutical Preparations industry, which witnessed a collective top-line improvement of 1.81% in the same period.

Acadia Pharmaceuticals Inc

Acadia Pharmaceuticals Inc's First Quarter Surge, Boosting Earnings by 2.593%

Acadia Pharmaceuticals Inc has recently released its financial results for the period ending March 31, 2023, and investors may be interested to know that the company has managed to improve its earnings compared to the previous year. The earning per share (EPS) loss for the most recent quarter improved to $-0.27 per share compared to $-0.70 per share, while the company's revenue grew by a small margin of 2.593% to $118.46 million in the current quarter. However, revenue has deteriorated by -13.208% from $136.49 million in the previous quarter.
Acadia Pharmaceuticals Inc has also reported a net deficit of $-43.021 million in the current quarter, which is an improvement over the $-113.056 million in the previous year's quarter. These numbers are a reflection of the company's dedication to improving its financial standing and profitability, which is a good sign for investors who are looking for long-term growth potential.






 

Acadia Pharmaceuticals Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com